Results 111 to 120 of about 6,183 (280)
Neuropeptides and peptide hormones in syncope and orthostatic intolerance [PDF]
, 2014 Syncope and orthostatic intolerance (OI) are common clinical syndromes often requiring medical attention. The former is defined as transient loss of consciousness and postural tone due to self-limited cerebral hypoperfusion, while the latter consists of ...
Benditt, David G., Krishnan, Balaji
core +2 more sources
Clinical Pharmacology in Drug Development, Volume 13, Issue 10, Page 1130-1142, October 2024.Abstract ASP8302 is an orally administered positive allosteric modulator of the muscarinic M3 receptor. Two Phase 1 studies were conducted, a first‐in‐human study in Europe and a Japanese phase 1 study. Both were randomized, participant‐ and investigator‐blinded, placebo‐controlled, single and multiple ascending oral doses, parallel group, clinical ...
Shin Takusagawa +13 more
wiley +1 more source
Updates on potential therapeutic targets in MSA
Advances in Clinical Neuroscience & Rehabilitation, 2016 Research into the genetic and molecular mechanisms underlying MSA has grown significantly in recent years. No neurorestorative treatments for MSA are available to date but there are many ongoing trials targeting α-syn pathways.
Viorica Chelban +2 more
doaj +1 more source
Journal of Medical Case Reports, 2020 Background Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. It has been shown to be useful predominantly with neurogenic orthostatic hypotension secondary to Parkinson’s disease ...
Annie H. Ho +4 more
doaj +1 more source
Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia
Clinical Endocrinology, Volume 101, Issue 4, Page 346-358, October 2024.Abstract Patients with salt‐wasting congenital adrenal hyperplasia (SW‐CAH) usually show pronounced impairment of aldosterone secretion and, therefore, also require mineralocorticoid replacement. While a lot of research and discussion focusses on the glucocorticoid therapy in SW‐CAH to replace the missing cortisol and to control adrenal androgen excess,
Katharina Lang +2 more
wiley +1 more source
Midodrine Hydrochloride in Patients on Hemodialysis with Chronic Hypotension
Renal Failure, 1996 Chronic hypotension, volume nonresponsive, is not rare in hemodialysis patients and is usually refractory to various therapies. Midodrine hydrochloride is an alpha-mimetic drug acting directly on the peripheral alpha-receptor and increases blood pressure.
Chiu-Ching Huang, Ji-Tseng Fang
openaire +3 more sources
Hemodynamic Effects of Midodrine After Space Flight in Astronauts Without Orthostatic Hypotension [PDF]
Orthostatic hypotension and presyncope are common and potentially serious risks for astronauts returning from space. Susceptible subjects fail to generate an adequate adrenergic response to upright posture. The -1 adrenergic agonist, midodrine, may be an
Meck, Janice V. +3 more
core +1 more source
Journal of Research in Medical Sciences, 2011 Background: In cirrhotic patients peripheral vasodilatation may decrease renal blood flow and subsequently raises plasma renin activity. Octreotide with several mechanisms causes peripheral arterial vasoconstriction.
Mohammad Minakari +3 more
doaj
Use of fludrocortisone for intradialytic hypotension
Kidney Research and Clinical Practice, 2018 Intradialytic hypotension during dialysis adversely affects a patient's prognosis and increases mortality. We report a case in which intradialytic hypotension that persisted after the administration of midodrine was relieved after the use of ...
Yuri Seo +5 more
doaj +1 more source
Frontiers in Physiology, 2014 Severely affected patients with autonomic failure require pressor agents to counteract the blood pressure fall and improve presyncopal symptoms upon standing.
Amy C Arnold +9 more
doaj +1 more source